



Navrongo Health Research Centre
Research & Development Division
Ghana Health Service
Post Office Box 114
Navrongo, UER.
Ghana



+233-245279984/
+233-243137130



patrick.ansah@navrongo-hrc.org
director@navrongo-hrc.org



UK-0043-7777



27 August 2025

My Ref.....

Your Ref.....

Prof. Henning Gädeke

c/o Prof. Michael Makanga

Global Health EDCTP3 Joint Undertaking

56 – 60 Avenue de la Toison d'Or

1060 Brussels

Belgium

Letter of endorsement

Dear Sir/Madam,

On behalf of Navrongo Health research Centre, P.O. Box 114, Navrongo , UE/R, Ghana, West Africa; VAT number: V0010749608 and in accordance with Council Regulation (EU) No 2085/2021 of 19th November 2021 establishing the joint undertakings under Horizon Europe and specifically Article 9 therein, I hereby submit an application to become a contributing partner to the Global Health EDCTP3 Joint Undertaking (Global Health EDCTP3 JU).

The Navrongo Health Research Centre (NHRC) is a Centre of Excellence, conducting of high impact evidence-based research into public health issues in resource-constrained settings in sub-Saharan Africa for local and global health policy formulation. It's core research focuses on, socio-economic burden of infectious diseases, conducting clinical trials into emerging, neglected and re-emerging infectious diseases in sub-Saharan Africa as well as socio-economic and demographic determinant of health.

Since its inception, research output from NHRC has influenced key health policies locally and globally. A few include universal coverage of Long-Lasting Insecticidal Net (LLIN) as a preventive strategy against malaria in malaria-endemic regions, inclusion of pediatric conjugate meningococcal vaccine in national expanded program of immunization (EPI) schedules in the African Meningitis belt.

Additionally, research conducted at NHRC has leapfrogged the re-organization of health delivery strategies for significant reduction in morbidity and mortality of most vulnerable populations. A few examples include intermittent preventive treatment in infants and pregnant women, the Community -Based Health Planning and Service (CHPS) concept. Universal Health Equity/Coverage and piloted the Nation Health Insurance Scheme, providing empirical data for a national scale-up in Ghana.

NHRC has a very strong research capacity development for African research scientist through collaboration with global institutions of high repute.

The Centre has one of the longest surveillances on meningococcal carriage in Ghana which serves to monitor and alert on possible epidemic outbreaks. There is an experienced team on epidemic-preparedness planning and execution experts who contributed significantly to the national strategy for the management of the COVID-19 pandemic in Ghana.

It is significant to mention that the NHRC's vision and mission very much align with the common objectives of Global Health EDCTP3 JU and continually strives to make significant contribution to global health advancement.

Contribution to Global Health based on research findings from NHRC over the past 30 years include the following:

- i. Inclusion of oral Vitamin A supplement to national EPI for child survival
- ii. Inclusion of MenAfriVac in national EPI and national vaccination campaigns in the African Meningitis Belt since 2012 to date.
- iii. Universal coverage of LLIN for under-five years and pregnant women.
- iv. Implantation of CHPS concept in African countries to bring health care closer to communities to reduce morbidity and mortality from preventable causes
- v. Training of health research scientist who are continually making significant contribution to the advancement of global health.

Also, the NHRC has developed culturally appropriate strategies for community and key-stakeholder engagements which facilitate introduction of new health interventions in its operational area. The extensive experience and expertise over the past 30 years provides potential added value for the achievement of the objectives of the Global Health EDCTP3 JU in sub-Saharan Africa.

Specifics of proposed involvement for example: project areas, work packages, deliverables, topics/entities to be funded.]

Project area	Work package	Deliverables	Entities to be funded
Accelerating development and integration of therapeutics against	Tuberculosis		Research and Innovation Action (RIA)

Neglected Tropical Diseases (NTDs) in sub-Saharan Africa			
Creating a sustainable clinical trial network for infectious diseases in sub-Saharan Africa	Research capacities, networking and training (Coordination and Support Actions)		Coordination and Support Action (CSA)
Genomic epidemiology for surveillance and control of poverty-related and emerging/re-emerging infections in sub-Saharan Africa	Emerging/re-emerging infectious diseases		Research and Innovation Action (RIA)
Global Health EDCTP3 Training Networks – Clinical Research Fellowships	Research capacities, networking and training (Coordination and Support Actions)		Coordination and Support Action (CSA)
Improving modes of delivery, deployment, and uptake of vaccines through phase iv/implementation research	Malaria		Research and Innovation Action (RIA)
Strengthening ethics and regulatory capacity	Research capacities, networking and training (Coordination and Support Actions)		Coordination and Support Action (CSA)
Research on existing Malaria vaccines and development of new promising candidates	Malaria		Research and Innovation Action (RIA)

Considering our contribution to public health and clinical research, Dr Patrick Ansah and his team are well positioned to lead workstream 12 which will focus on Scientific Leadership, Partnership and Networking, Capacity Assessment and Infrastructure strategy, Ethics, Regulatory and Pharmacovigilance, Clinical research and Trial Management, Social impact, Data Science, Artificial Intelligence (Ai) and Analytics and finally Capacity Strengthening and

training We estimate the total value of our contribution to be EUR 797,500 for the five year grant period.

We confirm the following:

1. We will comply with the Horizon Europe Regulation (EU) No 2021/695; Council Regulation (EU) No 2085/2021 establishing the joint undertakings under Horizon Europe; the Model Grant Agreement for Horizon Europe and applicable Global Health EDCTP3 JU rules, including the relevant work programmes, and particularly the call conditions therein.
2. We will keep all information received in the context of our involvement as contributing partner to the Global Health EDCTP3 JU confidential. This confidentiality obligation applies but is not limited to the areas of Global Health EDCTP3 JU call topic preparation and publication, proposal submission and evaluation, and consortium formation. We further understand that this obligation strictly prohibits the release of confidential information to any legal entities save where specifically authorised by Global Health EDCTP3 JU. Internal dissemination of information within our organisation will be done based on the “need-to-know” principle.
3. We are confident of our ability to fulfil the above commitments and further confirm our understanding that the Global Health EDCTP3 JU will allocate resources to the above topic based on these commitments.
4. The value of our contribution will be based on costs calculated in accordance with Article 6 of the Horizon Europe Model Grant Agreement.
5. We accept that additional modalities regarding the provision of our contribution may be defined in subsequent agreements or documents, such as a funding agreement and topic text.

Thank you

Yours faithfully,



Dr Patrick Odum Ansah

Director,

Navrongo Health research Centre